MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584776 | Name: M 79175

Description:

WARNING: This product is for research use only, not for human or veterinary use.

M 79175 is an aldose reductase inhibitor.

Chemical Structure

M 79175
M 79175
CAS#82319-87-7

Theoretical Analysis

MedKoo Cat#: 584776

Name: M 79175

CAS#: 82319-87-7

Chemical Formula: C12H11FN2O3

Exact Mass: 250.0754

Molecular Weight: 250.23

Elemental Analysis: C, 57.60; H, 4.43; F, 7.59; N, 11.20; O, 19.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
M 79175; E-1008
IUPAC/Chemical Name
Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2',5'-dione, 6-fluoro-2,3-dihydro-2-methyl-
InChi Key
SEAQTHCVAGBRFY-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H11FN2O3/c1-6-5-12(10(16)14-11(17)15-12)8-4-7(13)2-3-9(8)18-6/h2-4,6H,5H2,1H3,(H2,14,15,16,17)
SMILES Code
O=C1NC2(C(N1)=O)CC(C)OC3=CC=C(F)C=C23
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 250.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kador PF, Wyman M, Oates PJ. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®). Prog Retin Eye Res. 2016 Sep;54:1-29. doi: 10.1016/j.preteyeres.2016.04.006. Epub 2016 Apr 19. Review. PubMed PMID: 27102270. 2: Kador PF, Kinoshita JH, Sharpless NE. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J Med Chem. 1985 Jul;28(7):841-9. Review. PubMed PMID: 3925146. 3: Kato A, Horie T, Ishibashi Y, Miyake Y, Iwata S. Corneal permeability of aldose reductase inhibitor, M79175. II. In vivo study on pharmacokinetic aspect. J Ocul Pharmacol. 1986 Summer;2(3):287-94. PubMed PMID: 3139809. 4: Sato S, Takahashi Y, Wyman M, Kador PF. Progression of sugar cataract in the dog. Invest Ophthalmol Vis Sci. 1991 May;32(6):1925-31. PubMed PMID: 1903366. 5: Hotta N, Sakamoto N. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications]. Nihon Rinsho. 1987 Dec;45(12):3010-27. Review. Japanese. PubMed PMID: 3128677. 6: Kador PF, Akagi Y, Terubayashi H, Wyman M, Kinoshita JH. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1988 Aug;106(8):1099-102. PubMed PMID: 3401138. 7: Sato S, Mori K, Wyman M, Kador PF. Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175. Exp Eye Res. 1998 Feb;66(2):217-22. PubMed PMID: 9533847. 8: Cusick M, Chew EY, Ferris F 3rd, Cox TA, Chan CC, Kador PF. Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Arch Ophthalmol. 2003 Dec;121(12):1745-51. PubMed PMID: 14662595. 9: Neuenschwander H, Takahashi Y, Kador PF. Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. J Ocul Pharmacol Ther. 1997 Dec;13(6):517-28. PubMed PMID: 9436155. 10: Wada E. r-Galactonolactone in experimental galactosemic animals. Arch Biochem Biophys. 1986 Nov 15;251(1):215-21. PubMed PMID: 3098177. 11: Poulsom R. Comparison of aldose reductase inhibitors in vitro. Effects of enzyme purification and substrate type. Biochem Pharmacol. 1987 May 15;36(10):1577-81. PubMed PMID: 3109423. 12: Poulsom R. Inhibition of hexonate dehydrogenase and aldose reductase from bovine retina by sorbinil, statil, M79175 and valproate. Biochem Pharmacol. 1986 Sep 1;35(17):2955-9. PubMed PMID: 3091036. 13: Kador PF, Takahashi Y, Sato S, Wyman M. Amelioration of diabetes-like retinal changes in galactose-fed dogs. Prev Med. 1994 Sep;23(5):717-21. PubMed PMID: 7845946. 14: Kador PF, Randazzo J, Babb T, Koushik K, Takamura Y, Zhu W, Blessing K, Kompella UB. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther. 2007 Apr;23(2):116-23. PubMed PMID: 17444799. 15: Ashizawa K, Uchikawa K, Hattori T, Sato T, Miyake Y. Polymorphic differences in alpha- and beta-form crystals of 2R, 4S, 6-fluoro-2-methyl-spiro[chroman-4,4'-imidazoline]-2',5-dione (M79175) as determined by X-ray diffraction, infrared spectroscopy, and differential scanning calorimetry. J Pharm Sci. 1988 Jul;77(7):635-7. PubMed PMID: 3171953. 16: Horie T, Kitada M, Yoshioka H, Kanakubo Y, Omura T. 6-Fluoro-2-methylspiro(chroman-4,4'-imidazolidine)-2',5'-dione and related compounds as inducers of monooxygenase in rat liver microsomes. Drug Metab Dispos. 1987 Jul-Aug;15(4):560-4. PubMed PMID: 2888631. 17: Funada M, Okamoto I, Fujinaga Y, Yamana T. Effects of aldose reductase inhibitor (M79175) on ERG oscillatory potential abnormalities in streptozotocin fructose-induced diabetes in rats. Jpn J Ophthalmol. 1987;31(2):305-14. PubMed PMID: 3118085. 18: Teshima R, Taura T, Okamura R. Inhibition of in utero galactose-induced cataract development by an aldose reductase inhibitor in rat--electron microscopic study. Jpn J Ophthalmol. 1993;37(2):192-8. PubMed PMID: 8230845. 19: Ashizawa K. Polymorphism and crystal structure of 2R,4S,6-fluoro-2-methyl-spiro[chroman-4,4'-imidazoline]-2',5-dione (M79175). J Pharm Sci. 1989 Mar;78(3):256-60. PubMed PMID: 2724085. 20: Akagi Y, Kador PF. Effect of aldose reductase inhibitors on the progression of retinopathy in galactose-fed dogs. Exp Eye Res. 1990 Jun;50(6):635-9. PubMed PMID: 2115453.